Method Development and Validation of simultaneous estimation for Ramipril and Amlodipine besylate by UV- VISIBLE Spectrophotometric method

Abstract

This experiment shares the method development and analytical validation of an original, accurate and correct UV-Visible Spectrophotometric methods for the fixed dose assessment of Ramipril and Amlodipine besylate. The working solutions of Telmisartan and Ramipril were scanned at 240 nanometer and 210nanometer respectively. The regression strength of Amlodipine besylate and Ramipril over its absorbances take place as y=0.4291x0.0084 and y=0.0399x-0.310 respectively with a correlation coefficient (r²) of 0.9998 for Amlodipine besylate and 0.9993 for Ramipril. The intra-day precision in addition inter-day precision for Amlodipine besylate and its % RSD were obtained as 0.08% and 0.25% respectively. The intra-day precision in addition interday precision for Ramipril and% RSD were obtained as 0.16% and 0.24% respectively. The precise amount of tablet formulation were added which holds Alkaline (0.1 N Sodium hydroxide), Acidic (0.1 N Hydrochloric acid) reflux for 3 hours, 3% Oxydol at 50ºC, heat (60ºC), humidity (75 percentage Relative humidity) for 24 hr. and after the particular time diluted to distilled water, separated using Filter paper. From this stock solution, 5 mL section of the filtrate was pipetted out and further thinned with distilled water in a 100 mL standard flask (10 µg/mL). The standard stock solution of two drugs were prepared and compared against a label claim.